Cyanotic newborn and critical congenital heart disease screening

A baby in the postnatal ward looks dusky at feed time but settles in oxygen; or a term infant collapses at forty-eight hours, grey and gasping, the femoral pulses vanished; or a routine oxygen-saturation check on the second day returns 82 per cent and the nursing staff cannot believe the child looks well. The fellowship task in each is the same: treat a low oxygen saturation in a neonate as a heart lesion until an echocardiogram proves otherwise, apply the pulse-oximetry thresholds without softening them, and reopen the duct before the baby arrests. ^{[1] [3]}

Overview & Definition

A cyanotic newborn is an infant whose blood is carrying deoxygenated haemoglobin in the systemic circulation, and the colour is the visible end of a pathophysiological process that may be cardiac, pulmonary, neurological or haematological. Critical congenital heart disease narrows that list to the structural heart defects that threaten life in the first year and need surgery or a catheter procedure, and the cyanotic subgroup of those defects works by shunting venous blood across into the arterial side without passing through the lungs. The fellowship skill is to hold both ideas at once: cyanosis is a sign, and CCHD is the subset of causes where delay kills. ^{[2] [7]}

Newborn screening for CCHD is the structured programme that looks for these lesions before they declare themselves as collapse. It has three layers — antenatal ultrasound, the newborn clinical examination, and pulse oximetry at or after 24 hours of age — and the layers fail independently, which is why they are stacked. No single layer is sensitive enough on its own, and the pulse-oximetry layer exists specifically to catch the duct-dependent lesions that look well at birth and close their ductus on the second or third day. ^{[1] [10]}

The reason the topic carries critical priority is that the missed lesion behaves as a time bomb. A duct-dependent circulation supplies the body through the ductus arteriosus while it stays open, and the duct closes physiologically in the first days of life. When it closes in a baby who needs it, systemic or pulmonary blood flow is lost, the child becomes profoundly hypoxaemic and acidotic, and without prostaglandin E1 to reopen it the outcome is shock, end-organ injury and death. The whole screening programme exists to find that child before the duct closes, not after. ^{[2] [8]}

References12ShowHide

1. [1]de-Wahl Granelli A, Wennergren M, Sandberg K, Mellander M, Bejlum C, Inganäs L, Eriksson M, Segerdahl N, Agren A, Ekman-Joelsson BM, Sunnegårdh J, Verdicchio M, Ostman-Smith I. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ, 2009.PMID 19131383
2. [2]Mahle WT, Newburger JW, Matherne GP, Smith FC, Hoke TR, Koppel R, Gidding SS, Beekman RH 3rd, Grosse SD. Role of pulse oximetry in examining newborns for congenital heart disease: a scientific statement from the American Heart Association and American Academy of Pediatrics. Circulation, 2009.PMID 19581492
3. [3]Ewer AK, Middleton LJ, Furmston AT, et al. Pulse oximetry screening for congenital heart defects in newborn infants (PulseOx): a test accuracy study. Lancet, 2011.PMID 21820732
4. [4]Thangaratinam S, Brown K, Zamora J, Khan KS, Ewer AK. Pulse oximetry screening for critical congenital heart defects in asymptomatic newborn babies: a systematic review and meta-analysis. Lancet, 2012.PMID 22554860
5. [5]Plana MN, Zamora J, Suresh G, Fernandez-Pineda L, Thangaratinam S, Ewer AK. Pulse oximetry screening for critical congenital heart defects. Cochrane Database Syst Rev, 2018.PMID 29494750
6. [6]Zhao QM, Ma XJ, Ge XL, et al. Pulse oximetry with clinical assessment to screen for congenital heart disease in neonates in China: a prospective study. Lancet, 2014.PMID 24768155
7. [7]van der Linde D, Konings EE, Slager MA, Witsenburg M, Helbing WA, Takkenberg JJ, Roos-Hesselink JW. Birth prevalence of congenital heart disease worldwide: a systematic review and meta-analysis. J Am Coll Cardiol, 2011.PMID 22078432
8. [8]Aykanat A, Yavuz T, Özalkaya E, Topçuoğlu S, Ovalı F, Karatekin G. Long-Term Prostaglandin E1 Infusion for Newborns with Critical Congenital Heart Disease. Pediatr Cardiol, 2016.PMID 26260095
9. [9]Vari D, Xiao W, Behere S, Spurrier E, Tsuda T, Baffa JM. Low-dose prostaglandin E1 is safe and effective for critical congenital heart disease: is it time to revisit the dosing guidelines? Cardiol Young, 2021.PMID 33140712
10. [10]Ewer AK. Review of pulse oximetry screening for critical congenital heart defects in newborn infants. Curr Opin Cardiol, 2013.PMID 23381095
11. [11]Zhao QM, Niu C, Liu F, Wu L, Ma XJ, Huang GY. Accuracy of cardiac auscultation in detection of neonatal congenital heart disease by general paediatricians. Cardiol Young, 2019.PMID 31012400
12. [12]Hu XJ, Zhao QM, Ma XJ, Yan WL, Ge XL, Jia B, Liu F, Wu L, Ye M, Huang GY. Pulse oximetry could significantly enhance the early detection of critical congenital heart disease in neonatal intensive care units. Acta Paediatr, 2016.PMID 27540721